Neomycin and polymyxin B (Maxitrol) - Uses, Dose, Side effects, MOA

Neomycin and polymyxin B (Maxitrol) is a combination of non-absorbable antibiotics that are used for bladder irrigation in patients who develop bacteriuria due to prolonged bladder catheterization.

Neomycin and polymyxin B (Maxitrol) Uses:

  • Urinary bladder irrigant:

    • It is used as a bladder irrigant (for short-term use of up to 10 days) in patients who have bacteriuria due to the use of long-term indwelling catheters to prevent bacteria and septicemia.

Neomycin and polymyxin B (Maxitrol) Dose in Adults

Neomycin and polymyxin B Dose in the treatment of Urinary bladder irrigant:

  • Intravesical:
    • Add 1 mL irrigant to 1,000 ml isotonic saline solution per day as continuous irrigation for up to 10 days.

Neomycin and polymyxin B (Maxitrol) Dose in Childrens

Neomycin and polymyxin B Dose in the treatment of Urinary bladder irrigant:

Note: The data is limited and the effectiveness of the drug varies. Most of the experience with the drug has been in patients with spinal cord injury or neurogenic bladder.

  • Children and Adolescents:

    • Irrigant solution (neomycin 40 mg/polymyxin B 200,000 units/L):
      • Intravesical: 10 mL instilled at the end of each catheterization and retained until next catheterization.
      • In older adolescents, 30 mL 2 to 3 times daily has been used for asymptomatic bacteriuria.
    • Note: Use has generally been replaced with other agents (eg, saline, gentamicin).

Pregnancy Category: C

  • Animal reproduction studies have not been conducted with this combination
  • There are reports of total irreversible bilateral congenital deafness in children whose mothers received streptomycin during pregnancy.
  • Talk to individual agents.

Use during breastfeeding:

 

  • It is unknown if the drug will be excreted into breastmilk.

Dose in Kidney Disease:

The manufacturer has not recommended any adjustments in the dose in patients with kidney disease.

Dose in Liver disease:

The manufacturer has not recommended any adjustments in the dose in liver disease.

Side effects of Neomycin and polymyxin B (Maxitrol):

  • Central Nervous System:

    • Localized Burning
  • Dermatologic:

    • Contact Dermatitis
    • Erythema
    • Skin Rash
    • Urticaria
  • Genitourinary:

    • Bladder Mucosa Irritation
    • Nephrotoxicity
  • Neuromuscular & Skeletal:

    • Neuromuscular Blockade
  • Otic:

    • Ototoxicity

Contraindications to Neomycin and polymyxin B (Maxitrol):

  • Allergy reactions to neomycin, neomycin B or any other component of the formulation
  • Patients who have had severe allergic reactions to aminoglycosides in the past.

Warnings and precautions

  • Superinfection

    • Long-term use of the drug can lead to fungal and bacterial superinfections, such as C. difficile-associated diarrhea or pseudomembranous collitis.
    • CDAD can occur even after two months of last antibiotic use.
  • Systemic toxicities:

    • Systemic absorption may lead to nephrotoxicity, ototoxicity, or neuromuscular blockade.
    • Systemic absorption can be more common in patients who have bladder defects or who have had surgery that has caused injury to the bladder wall.
  • Renal impairment

    • It can increase the risk of kidney toxicity. You should use it with caution.

Neomycin and polymyxin B: Drug Interaction

Risk Factor C (Monitor therapy)

Acarbose

Neomycin may enhance the adverse/toxic effect of Acarbose. Neomycin may decrease the metabolism of Acarbose.

Amphotericin B

May enhance the nephrotoxic effect of Aminoglycosides.

Arbekacin

May enhance the nephrotoxic effect of Aminoglycosides. Arbekacin may enhance the ototoxic effect of Aminoglycosides.

BCG Vaccine (Immunization)

Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization).

Bisphosphonate Derivatives

Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives.

Botulinum Toxin-Containing Products

Aminoglycosides may enhance the neuromuscularblocking effect of Botulinum Toxin-Containing Products.

Capreomycin

May enhance the neuromuscular-blocking effect of Polymyxin B.

CARBOplatin

Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.

Cardiac Glycosides

Aminoglycosides may decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration.

Cefazedone

May enhance the nephrotoxic effect of Polymyxin B.

Cephalosporins (2nd Generation)

May enhance the nephrotoxic effect of Aminoglycosides.

Cephalosporins (3rd Generation)

May enhance the nephrotoxic effect of Aminoglycosides.

Cephalosporins (4th Generation)

May enhance the nephrotoxic effect of Aminoglycosides.

Cephalothin

May enhance the nephrotoxic effect of Aminoglycosides.

Cephradine

May enhance the nephrotoxic effect of Aminoglycosides.

CISplatin

May enhance the nephrotoxic effect of Aminoglycosides.

CycloSPORINE (Systemic)

Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic).

Distigmine

Aminoglycosides may diminish the therapeutic effect of Distigmine.

Lactobacillus and Estriol

Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol.

Loop Diuretics

May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.

Nonsteroidal Anti-Inflammatory Agents

May decrease the excretion of Aminoglycosides. Data only in premature infants.

Oxatomide

May enhance the ototoxic effect of Aminoglycosides.

Regorafenib

Neomycin may decrease serum concentrations of the active metabolite(s) of Regorafenib.

SORAfenib

Neomycin may decrease the serum concentration of SORAfenib.

Tenofovir Products

Aminoglycosides may increase the serum concentration of Tenofovir Products. Tenofovir Products may increase the serum concentration of Aminoglycosides.

Vancomycin

May enhance the nephrotoxic effect of Aminoglycosides.

Vitamin K Antagonists (eg, warfarin)

Neomycin may enhance the anticoagulant effect of Vitamin K Antagonists.

Risk Factor D (Consider therapy modification)

Colistimethate

Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.

Neuromuscular-Blocking Agents

Polymyxin B may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.

Penicillins

May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. Exceptions: Amoxicillin; Ampicillin; Bacampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Benzathine; Penicillin V Potassium.

Sodium Picosulfate

Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.

Risk Factor X (Avoid combination)

Ataluren

May enhance the adverse/toxic effect of Aminoglycosides. Specifically, an increased risk of nephrotoxicity may occur with the concomitant use of ataluren and aminoglycosides.

Bacitracin (Systemic)

Polymyxin B may enhance the nephrotoxic effect of Bacitracin (Systemic).

Bacitracin (Systemic)

Neomycin may enhance the nephrotoxic effect of Bacitracin (Systemic).

BCG (Intravesical)

Antibiotics may diminish the therapeutic effect of BCG (Intravesical).

Cholera Vaccine

Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.

Foscarnet

May enhance the nephrotoxic effect of Aminoglycosides.

Mannitol (Systemic)

May enhance the nephrotoxic effect of Aminoglycosides.

Mecamylamine

Polymyxin B may enhance the neuromuscular-blocking effect of Mecamylamine.

Methoxyflurane

May enhance the nephrotoxic effect of Polymyxin B

Monitoring parameters:

  • Urinalysis,
  • renal function.

How to administer Neomycin and polymyxin B?

  • It is indicated only for the irrigation of the bladder and not for parenteral administration.
  • The inflow lumen of the 3-way catheter should be connected to the irrigation container to allow the continuous irrigation of the urinary bladder.
  • The bladder rinse should be continuous and the irrigation should not be interrupted for more than a few minutes.
  • The flow rate of the irrigation should be adjusted to 1 liter per 24 hours.
  • However, if the patients' urine output exceeds 2 liters per 24 hours, the flow rate should be set at a rate of 2 liters per 24 hours.

Mechanism of action of Neomycin and polymyxin B:

Neomycin:

  • It binds with the 30S subunit of the ribosomal ribosomal subunit, inhibits bacterial protein synthesis, and indirectly inhibits bacterial replication.

Polymyxin B

  • By binding to phospholipids, it damages the bacterial cell membrane. It causes a decrease in bacterial cellular permeability, which allows for the leakage intracellular content.

Talk to individual agents.

Absorption:

 

  • It is only minimally absorbed when used topically. Systemic absorption can occur if the bladder is inflamed or denuded.

International Brands of Neomycin and polymyxin B:

  • Neosporin G.U. Irrigant
  • Neosporin Irrigating Solution
  • Alosol
  • Isopto Statrol
  • Maxitrol
  • Statrol

Neomycin and polymyxin B Brands Names in Pakistan:

  • Maxitrol

Comments

NO Comments Found